HLX26

HLX26 is a monoclonal antibody developed by Shanghai Henlius Biotech. Its target is LAG-3 (the sponsor names LAG-3). The sponsor states: An anti-LAG-3 monoclonal antibody injection that blocks LAG-3 signalling to enhance T-cell mediated anti-tumour immunity, studied in combination with PD-1 inhibition and chemotherapy. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT05787613, plans to enrol 132 participants with primary completion expected 2026-02. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.